Drugs / OC-CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03362606 | Jun 2026 → Dec 2029 expected | ovarian cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362606 ↗ |
| Modality | Cell therapy | “ovarian cancer specific cytotoxic lymphocytes (OC-CTLs)” NCT03362606 ↗ |
| Route | Intravenous | “via IV, abdominal cavity or tumor injection each time” NCT03362606 ↗ |
| Route | Other | “via IV, abdominal cavity or tumor injection each time” NCT03362606 ↗ |